Brilinta Review Sparks War Of Words Between FDA Cardio-Renal Division’s Marciniak, Stockbridge

The ticagrelor NDA ignited strong opinions from the cross-discipline team leader about sponsor AstraZeneca’s conduct, drawing a forceful response from the review division director.